Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;4(10):1277-1294.
doi: 10.1038/s44161-025-00712-3. Epub 2025 Sep 24.

Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α

Affiliations

Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α

Sumeet A Khetarpal et al. Nat Cardiovasc Res. 2025 Oct.

Abstract

Endurance exercise promotes adaptive growth and improved function of myocytes, which is supported by increased mitochondrial activity. In skeletal muscle, these benefits are in part transcriptionally coordinated by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). The importance of PGC-1α to exercise-induced adaptations in the heart has been unclear. Here we show that deleting PGC-1α specifically in cardiomyocytes prevents the expected benefits from exercise training and instead leads to heart failure after just 6 weeks of training. Consistent with this, in humans, rare genetic variants in PPARGC1A, which encodes PGC-1α, are associated with increased risk of heart failure. In this model, we identify growth differentiation factor 15 (GDF15) as a key heart-secreted mediator that contributes to this dysfunction. Blocking cardiac Gdf15 expression improves cardiac performance and exercise capacity in these mice. Finally, in human heart tissue, lower cardiomyocyte PPARGC1A expression is associated with higher GDF15 expression and reduced cardiomyocyte density. These findings uncover a crucial role for cardiomyocyte PGC-1α in enabling healthy cardiac adaptation to exercise in part through suppression of GDF15.

PubMed Disclaimer

Conflict of interest statement

Competing interests: B.M.S. is an inventor on patent WO2015051007A1; the patent applicant is Dana Farber Cancer Institute. Inventors include B.M.S. and Christiane D. Wrann (not affiliated with this study). The application number is WO2015051007A1. Patent is currently active. No aspect of the current paper is covered in the patent application. A.A. is an inventor on patent US20210163495A1; the patent applicant is The General Hospital Corporation. Inventors include A.A. and several investigators unaffiliated with this study (R. T. Peterson, Y. Liu, B. Zheng, Y. Wang). The application number is US20210163495A1. The patent is currently active. No aspect of this paper is covered in the patent application. J.D.R. and A.R. are inventors on patent US11834508B2; patent applicants are Norvartis AG and Beth Israel Deaconess Medical Center. Inventors include J.D.R., A.R. and D. J. Glass (not affiliated with this study). The application number is US11834508B2. The patent is currently active. No aspect of the current study is covered in the patent application. In addition, we note the additional following competing interests. B.M.S. is an academic cofounder and consultant for Aevum Therapeutics, all unrelated to this current work. J.R. is a consultant for Takeda Neurosciences, unrelated to the current work. S.P. is currently employed by the Novartis Institute of Biomedical Research. J.D.R. has received research support from Amgen, Genentech and Keros, all unrelated to this current work. A.R. is a scientific founder of Thryv Therapeutics, unrelated to this current work. M.N. has received funds or material research support from Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon, Verseau Therapeutics and Bitterroot, all unrelated to the current work. A.A. reports on the Board of Directors of Corventum. The other authors declare no competing interests.

References

    1. Virani, S. S. et al. Heart Disease and Stroke Statistics-2021 update: a report from the American Heart Association. Circulation 143, e254–e743 (2021). - PubMed - DOI
    1. Campbell, K. L. et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med. Sci. Sports Exerc. 51, 2375–2390 (2019). - PubMed - PMC - DOI
    1. Contrepois, K. et al. Molecular choreography of acute exercise. Cell 181, 1112–1130 (2020). - PubMed - PMC - DOI
    1. Schmitz, K. H. et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer. J. Clin. 69, 468–484 (2019). - PubMed - PMC
    1. Myers, J. et al. Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 346, 793–801 (2002). - PubMed - DOI

MeSH terms

Substances

Grants and funding

LinkOut - more resources